Derma sapiens - Company finances
|
EUR
|
2021
From: 2021-11-30
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|
|
Financial data
|
|||||
| Sales revenue | - | 179,463 | 385,949 | 481,039 | 493,318 |
| Profit before tax | -2,941 | 9,889 | 33,502 | 13,187 | -53,274 |
| Net profit | -2,941 | 9,517 | 28,402 | 11,112 | -53,274 |
| Equity | 5,059 | 24,576 | 48,032 | 49,772 | -3,502 |
| Liabilities | - | 82,783 | 83,119 | 156,494 | 159,557 |
| Non-current assets | 0 | 63,006 | 88,583 | 153,526 | 128,667 |
| Current assets | 6,254 | 44,353 | 42,568 | 52,740 | 27,388 |
| Total assets | 6,254 | 107,359 | 131,151 | 206,266 | 156,055 |
|
Taxes paid
|
|||||
| STI taxes | - | - | 37,575 | 57,796 | 74,401 |
| Social insurance contributions | - | - | 16,386 | 30,021 | 44,494 |
|
Financial indicators
|
|||||
| Revenue change y/y | - | - | +115.1% | +24.6% | +2.6% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | -47.0% | 8.9% | 21.7% | 5.4% | -34.1% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | -58.1% | 38.7% | 59.1% | 22.3% | - |
| Profit margin Net profit margin. Shows the overall profitability of the company. | - | 5.3% | 7.4% | 2.3% | -10.8% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | - | 5.5% | 8.7% | 2.7% | -10.8% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | - | 3.4 | 1.7 | 3.1 | - |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | - | 59,821 | 68,108 | 64,139 | 64,346 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Derma sapiens - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2026-06-16 | 2026-06-16 | 2200.09 |
| 2025-09-16 | 2025-09-16 | 2501.31 |
| 2025-05-16 | 2025-05-18 | 2700.56 |
| 2024-05-02 | 2024-05-08 | 0.04 |
Derma sapiens - VMI tax arrears
| From | To | Overdue, € |
|---|---|---|
| 2026-04-22 | 2026-04-24 | 689.91 |
| 2026-03-19 | 2026-04-21 | 0.15 |
| 2026-02-28 | 2026-03-02 | 9.7 |
| 2026-02-21 | 2026-02-21 | 9.7 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Derma sapiens, MB (code 305946274) is a Small partnership engaged in medical specialists activities. In 2025, revenue increased to €493.3K from €481.0K in 2024 and €385.9K in 2023, reflecting 2.5% year-on-year growth and 27.8% growth over two years. Profitability weakened materially over the same period: net profit fell from €28.4K in 2023 to €11.1K in 2024 and turned into a €53.3K loss in 2025, with the profit margin declining to -10.8%. The balance sheet also deteriorated. Total assets decreased to €156.1K in 2025 from €206.3K a year earlier, while liabilities remained high at €159.6K. Equity turned negative at -€3.5K after €49.8K in 2024, indicating a weakened capital position. Asset turnover remained strong at 3.16x, and revenue per employee was €70.5K, but profit per employee was -€7.6K. Return metrics should be interpreted cautiously because of the negative equity base; ROA was -34.1% in 2025.